Literature DB >> 27759740

Goal-directed fluid management in free flap surgery for cancer of the head and neck.

Sanna L Lahtinen1,2, Janne H Liisanantti3,4, Meri M Poukkanen5, Päivi A Laurila6,3.   

Abstract

BACKGROUND: Goal-directed fluid management using stroke volume variation (SVV) analysis is not well studied in free flap reconstruction surgery in patients with head and neck cancer.
METHODS: Patients operated due to cancer of the head and neck with free flap reconstruction during 2008-2010 and 2012-2014 in Oulu University Hospital were retrospectively evaluated to determine the impact of SVV-guided fluid management on perioperative fluid balance, postoperative complications and hospital length of stay (LOS).
RESULTS: A total of 104 patients were included in the study and in 48 of them SVV was used to guide intraoperative fluid management. The SVV-guided fluid management led to significant reduction in intraoperative fluid load (6070 mL vs. 8185 mL) and hospital length of stay (11.5 vs. 14.0 days). There was no difference in the number of postoperative complications between the groups.
CONCLUSIONS: The SVV-guided fluid management reduces fluid administration in free flap reconstruction surgery with head and neck cancer.

Entities:  

Mesh:

Year:  2016        PMID: 27759740     DOI: 10.23736/S0375-9393.16.11451-8

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  2 in total

1.  Enhanced recovery after microvascular reconstruction in head and neck cancer - A prospective study.

Authors:  Jens H Højvig; Birgitte W Charabi; Irene Wessel; Lisa T Jensen; Jan Nyberg; Nana Maymann-Holler; Henrik Kehlet; Christian T Bonde
Journal:  JPRAS Open       Date:  2022-08-19

2.  Comparison of Stroke Volume Variation-based goal-directed Therapy Versus Standard Fluid Therapy in Patients Undergoing Head and Neck Surgery: A Randomized Controlled Study

Authors:  Nuray Turkut; Demet Altun; Nur Canbolat; Cansu Uzuntürk; Cömert Şen; Ali Emre Çamcı
Journal:  Balkan Med J       Date:  2022-08-15       Impact factor: 3.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.